Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Bexagliflozin demonstrated non-inferiority in reducing major adverse cardiovascular events (MACE+), with a hazard ratio (HR) of 0.80 (95% confidence interval (CI), 0.58 to 1.09). For MACE, the HR was 0.82 (95% CI, 0.59 to 1.13).
• In glycemic control, bexagliflozin significantly reduced Hemoglobin A1c (HbA1c) by -0.45 (95% CI: -0.55 to -0.34), Fasting Plasma Glucose (FPG) by -1.37 (95% CI: -1.73 to -1.00), body weight by -1.77 kg (95% CI: -2.44 to -1.10), and systolic blood pressure by -4.11 mmHg (95% CI: -6.18 to -2.03).
• Bexagliflozin showed a renal protective effect with a reduction in estimated Glomerular Filtration Rate (eGFR) of -3.48 (95% CI: -6.57 to -0.39), comparable to other Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors such as dapagliflozin and luseogliflozin.
• Bexagliflozin did not increase the risk of MACE in participants with type 2 diabetes mellitus (T2DM), with safety outcomes consistent with the placebo arm.
• Renal safety outcomes indicated a reduction in eGFR, similar to other SGLT2 inhibitors like luseogliflozin and dapagliflozin, without a significant increase in adverse renal events.
• The studies focused on participants with T2DM and chronic kidney disease, with no significant differences in effectiveness or safety among various population types or subgroups explicitly reported in the provided documents.